One of the most studied prostate cancer DNA vaccines encodes PAP plus granulocyte-macrophage colony stimulating factor (GM-CSF) (pTVG-HP), which has been tested in a phase I trial of men with biochemically recurrent PCa. Here, CSF2 is linked to prostate carcinoma.